Author  
Place of duty  
Title   위암 및 그외 소화기계 악성종양에서 혈청내 종양표지자 CA 72-4 측정의 진단적 유용도 ( Usefulness of CA 72-4 in Gastric Carcinoma and Other Gastrointestinal Malignancies )
Publicationinfo   1993 Jan; 025(03): 334-343.
Key_word   CA72-4, CEA, Gastric cancer, Gastrointestinal malignancies
Full-Text  
Abstract   Background: Gastric cancer is one of the most frequent cancers in Korea, but none of many available tumor markers has made an early diagnosis or monitoring of the development of gastric cancer possible. The serum levels of CA72-4 as a new tumor marker were measured by a radioimmunomet- ric assay for evaluating of its clinical significance as a possible tumor marker, especially in gastric cancer. Patients and Methods: The CA72-4 serum levels were measured in healthy control (n=39) and patients with benign (n=50) or malignant gastrointestinal diseases (n=241) containing gastric carcinoma (n=l55) using novel quantitative immunoradiometric assay. A cut off value of 6 U/ml was used. Results: 1) The median value of CA72-4 in gastric cancer was not different from that of the benign gastrointestinal disease or control group. 2) The specificity of CA72-4 was 92% in benign gastrointestinal disease. 3) The sensitivity of CA72-4 in gastric cancer was 38.1% and was not different from that of CEA(34.1%). 4) The sensitivity of CA72-4 was inferior to CA19-9 in pancreatic cancer(61.9% versus 85.7A ), biliary cancer(36.4% versus 86.3%, P<0.05) and inferior to CEA in calorectal cancer(48.0% versus 72.0%). 5) The positive rates of CA12-4 were higher in advanced gastric cancer(0% in stage I, 11 / in stage II, 25% in stage III, 51.2% in stage IV). 6) Elevated serum levels of CA72-4 in gastric cancer patients preoperatively decreased to below the cut off value after radical gastric surgery. 7) The serial CA72-4 levels of 9 unresectable gastric cancer patients who received palliative chemotherapy eorrelated roughly with tumor response. 8) There was no significant correlation between CA72-4 and CEA in gastric cancer. Conclusion: Our data indicates that CA72-4 had relatively low sensitivity for gestric cancer(38.1%) and should not be used as a screening test, but should permit the monitoring of follow-uy and the early detection of recurrences and therapeutic response.
저 자   안명주(Myung Ju Ahn),홍진선(Jin Sun Hong),황일란(II Ran Hwang),김상위(Sang We Kim),서철원(Cheol won Suh),이규형(Kyoo Hyung Lee),이정신(Jung Shin Lee),김명환(Myung Hwan Kim),민영일(Young Ii Min),김상희(Sang Hee Kim),이명혜(Myung Hae Lee)